SHR-A1811 plus Pertuzumab for HER2-altered lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two targeted drugs (SHR-A1811 and pertuzumab) as a second-line treatment for people with advanced lung cancer that has a HER2 change. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that has a HER2 change (mutation, amplification, or overexpression)
- You have already received at least one prior cancer treatment for your advanced lung cancer
- You have at least one tumor that can be measured on a scan
- You are in good physical condition (able to do daily activities without help)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two new drugs (SHR-A1811 and AK112) for people with a specific type of advanced lung cancer that has changes in the HER2 gene. It may help those whose cancer has gotten worse after one previous treatment, or who have not yet had any treatment for advanced disease.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
This trial tests a new drug called SHR-A1811 in patients with advanced, incurable lung cancer that has a specific genetic change in the HER2 gene. The drug may help slow or stop cancer growth by targeting this genetic change.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.